HLA-A*03:01 | easYmer kit
Product Code:
IMM-1016-01
IMM-1016-01
Regulatory Status:
RUO
RUO
Shipping:
Dry Ice
Dry Ice
Storage:
-20 °C
-20 °C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| IMM-1016-01-050 | 50 Tests | £956.00 |
Quantity:
| IMM-1016-01-100 | 100 Tests | £1,220.00 |
Quantity:
| IMM-1016-01-150 | 150 Tests | £1,749.00 |
Quantity:
| IMM-1016-01-200 | 200 Tests | £2,278.00 |
Quantity:
| IMM-1016-01-250 | 250 Tests | £2,807.00 |
Quantity:
| IMM-1016-01-300 | 300 Tests | £3,336.00 |
Quantity:
| IMM-1016-01-500 | 500 Tests | £3,865.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Denmark.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- References
- Show All
Further Information
Description:
HLA-Class I easYmer® is a highly active formulation of peptide-receptive HLA class I (HLA-I) molecules (no artificial Cys-bonds linking heavy chain and b2m). Add Peptides of interest to generate specific peptide-HLA class I monomers. The loading efficacy can be validated in a FACS-based bead assay. The monomers can easily be tetramerised with fluorophore-conjugated streptavidin and used to stain cognate T cells for analysis in a flow cytometric assay. The easYmer® technology seamlessly enables: Large-scale production of pMHC monomers with a single epitope for screening a large number of samples, parallel production and screening of pMHC monomers with many different peptide epitope candidates and screening and validation of peptide-HLA-I binding. easYmers® are available in aliquots of 50 Tests (corresponding to 20 ug of pMHC)
References
- Boettler, T; et.al.; SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis; Journal of hepatology; 2022; 77(3):653-659PubMed ID:35461912; DOI: 10.1016/j.jhep.2022.03.040; https://www.sciencedirect.com/science/article/pii/S0168827822002343
- Oberhardt, V; et.al.; Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine; Nature; 2021; 597(7875):268-273PubMed ID:34320609; DOI: 10.1038/s41586-021-03841-4; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426185
- Azoury, ME; et. al.; Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice; Diabetes; 2020; 69(12):2678-2690PubMed ID:32928873; DOI: 10.2337/db20-0013; https://diabetesjournals.org/diabetes/article-abstract/69/12/2678/16468
- Thimme, R; et.al.; Rapid and stable mobilization of fully functional spike-specific CD8+ T cells preceding a mature humoral response after SARS-CoV-2 mRNA vaccination; Research Square; 2021; ():PubMed ID:; DOI: 10.21203/rs.3.rs-505193/v1; https://www.nature.com/articles/s41586-021-03841-4
- Vecchio, F; et.al.; Coxsackievirus infection induces direct pancreatic ?-cell killing but poor anti-viral CD8+ T-cell responses; bioRxiv : the preprint server for biology; 2023; ():PubMed ID:37662376; DOI: 10.1101/2023.08.19.553954; https://www.ncbi.nlm.nih.gov/pubmed/37662376
- Zimmermann, C; et.al.; Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids; Proceedings of the National Academy of Sciences of the United States of America; 2024; 121(9):e2315985121PubMed ID:38377192; DOI: 10.1073/pnas.2315985121; https://www.pnas.org/doi/abs/10.1073/pnas.2315985121
- Vecchio, F; et.al.; Coxsackievirus infection induces direct pancreatic ? cell killing but poor antiviral CD8+ T cell responses; Science advances; 2024; 10(10):eadl1122PubMed ID:38446892; DOI: 10.1126/sciadv.adl1122; http://dx.doi.org/10.1126/sciadv.adl1122
- Shoumariyeh, K; et.al.; Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma; Vaccines; 2024; 12(11):PubMed ID:39591152; DOI: 10.3390/vaccines12111249; http://dx.doi.org/10.3390/vaccines12111249